Noetik

Emerging

AI-native biotech building cancer biology foundation models. $50M GSK licensing deal. $62M raised. Founded 2022, SF.

AI Cancer Biology & Drug Discovery
Visit Website
Updated April 2026

Company Overview

About Noetik

Noetik is a San Francisco AI-native biotech founded 2022. Builds foundation models simulating tumor biology for cancer immunotherapy drug discovery. Maps tumor microenvironment interactions to identify therapeutic targets.

Business Model & Competitive Advantage

Raised $62M: $14M seed (2023) and $40M Series A (2024, Polaris Partners). Early 2026: landmark $50M GSK deal (upfront + milestones) for nonexclusive license to NSCLC and colorectal cancer models. Also partnered with Agenus (2025).

Competitive Landscape 2025–2026

Validates AI licensing model for tech-bio: building foundation models that pharma partners use for drug discovery.

Revenue
$50M
Curated content • Fact-checked and verified
Loading News...
Loading Culture...

Open Positions

Reddit Discussions

Loading Competitive Intelligence...

Key Differentiators

Emerging Innovator

Noetik is an emerging player bringing innovative solutions to the Healthcare Tech market.

Frequently Asked Questions

Compare Noetik with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

Start Comparison →
For Noetik

Claim This Profile

Are you from Noetik? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Noetik Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Noetik vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →